Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.

ABSTRACT:

Objective

Aberrant DNA methylation is an early event in carcinogenesis which could be leveraged to detect ovarian cancer (OC) in plasma.

Methods

DNA from frozen OC tissues, benign fallopian tube epithelium (FTE), and buffy coats from cancer-free women underwent reduced representation bisulfite sequencing (RRBS) to identify OC MDMs. Candidate MDM selection was based on receiver operating characteristic (ROC) discrimination, methylation fold change, and low background methylation among controls. Blinded biological validation was performed using methylated specific PCR on DNA extracted from independent OC and FTE FFPE tissues. MDMs were tested using Target Enrichment Long-probe Quantitative Amplified Signal (TELQAS) assays in pre-treatment plasma from women newly diagnosed with

SUBMITTER: Marinelli LM 

PROVIDER: S-EPMC9133226 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature